Drug Trial Radar · NCT00126438
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: Mar 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
515
Actual
Start
Jul 2005
Primary completion
Jul 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease.
Conditions
- Heart Failure, Congestive
Interventions
123I-mIBG (meta-iodobenzylguanidine)Drug
Single Dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) RatioTime frame: Approximately 24 months from the date of administration of 123I-mIBG
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GE Healthcare
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.